SEARCH

SEARCH BY CITATION

References

  • 1
    Fisher ER, Gregorio RM, Fisher B. The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project ( protocol no. 4). Cancer 1975; 36: 185.
  • 2
    Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968; 168: 33756.
  • 3
    Fisher ER, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project ( protocol no. 4): VI. Discriminants for five-year treatment failure. Cancer 1980; 46: 90818.
  • 4
    Fisher ER, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project ( protocol no. 4): X. Discriminants for tenth-year treatment failure. Cancer 1984; 53: 71223.
  • 5
    Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983; 52: 15517.
  • 6
    Fisher ER, Palekar AS, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project ( protocol no. 4): IX. Scar cancers. Breast Cancer Res Treat 1983; 3: 3959.
  • 7
    Adair F, Berg J, Joubert L, Robbins GF. Long term follow-up of breast cancer patients: the 30 year report. Cancer 1974; 33: 114550.
  • 8
    Dawson PJ, Ferguson DJ, Karrison T. The pathologic findings of breast cancer patients surviving 25 years after radical mastectomy. Cancer 1982; 50: 21318.
  • 9
    Sutherland C, Mather FJ. Long-term survival and prognostic factors in patients with regional breast cancer (skin, muscle, and/or chest wall attachment). Cancer 1985; 55: 138997.
  • 10
    Dawson PJ, Karrison T, Ferguson DJ. Histologic features associated with long-term survival in breast cancer. Hum Pathol 1986; 17: 101521.
  • 11
    Sutherland CM, Mather FJ. Long-term survival and prognostic factors in breast cancer patients with localized (no skin, muscle, or chest wall attachment) disease with and without positive lymph nodes. Cancer 1986; 57: 6229.
  • 12
    Contesso G, Friedman S, Mouriesse H, Rouesse J. The importance of histoprognostic grading as a factor in long term survival in breast cancer. Proc Am Soc Clin Oncol 1987; 6: A194.
  • 13
    Yang JH, Slack NH, Nemoto T. Effect of axillary nodal status on the long-term survival following mastectomy for breast carcinoma: nodal metastases may not always suggest systemic disease. J Surg Oncol 1987; 36: 2438.
  • 14
    Sutherland CM, Mather FJ. Charity hospital experience with long term survival and prognostic factors in patients with breast cancer with localized or regional disease. Ann Surg 1988; 207: 56980.
  • 15
    Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. A long term follow-up study of survival in stage I (T, N° M°) and stage II (T, N1 M°) breast carcinoma. J Clin Oncol 1989; 7: 35566.
  • 16
    Toikkanen SP, Joensuu H. Prognostic factors and long-term survival in breast cancer in a defined urban population. APMIS 1990; 98: 100514.
  • 17
    Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187220.
  • 18
    Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699713.
  • 19
    Fisher B, Slack NH, Bross IDJ. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969; 24: 107180.
  • 20
    Fisher ER, Redmond C, Fisher B, Bass G. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP): prognostic discriminants for 8 year survival for node negative invasive breast cancer patients. Cancer 1990; 65: 21218.
  • 21
    Fisher ER, Anderson S, Redmond C, Fisher B. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol 1992; 8: 1616.
  • 22
    Fisher ER, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project: VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 1983; 51: 18191.
  • 23
    Fisher ER, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project: correlations with concordant and discordant estrogen and progesterone receptors. Cancer 1987; 59: 15549.
  • 24
    Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project protocol B-06. J Clin Oncol 1988; 6: 107687.
  • 25
    Fisher B, Gunduz N, Constantino J, Fisher ER, Redmond C, Mamounas ER, et al. DNA flow cytometric analysis of primary operable breast cancer: relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 1991; 68: 146575.
  • 26
    Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathological findings from National Surgical Adjuvant Breast Project (protocol B-06): prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 10312.
  • 27
    Toikkanen SP. Prognostic factors in breast cancer: a long-term survival study with special reference to nuclear DNA content. Diss Abstr Int (C) 1990; 51: 429.
  • 28
    Yuan J, Hennessy C, Corbett IP, Givan AL, Shenton BK, Dykin R, et al. DNA ploidy in human breast cancer: its relationship to other indicators of poor prognosis and to long-term survival. Br J Cancer 1990; 62 (Suppl 12): 6.
  • 29
    Yuan J, Hennessy C, Corbett IP, Dykin R, Givan AL, Shenton BK, et al. Node negative breast cancer: the prognostic value of DNA ploidy for long-term survival. Br J Surg 1991; 78: 8448.
  • 30
    Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985; 6: 32733.
  • 31
    Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of her2, PS2 and S-phase on relapse, hormonal therapy response and long-term survival in primary breast cancer. Proc Annu Meet Am Assoc Cancer Res 1991; 32: A1005.
  • 32
    Tsuda H, Hirohashi S, Shimosata Y, Hirota T, Tsugane S, Yamamoto H, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogenecoamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 1989; 49: 31048.
  • 33
    Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990; 81: 32732.